Nile Therapeutics, Inc.

Nile Therapeutics is a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular disease and other areas of unmet medical need.

Cenderitide is a novel chimeric natriuretic peptide in Phase 2 clinical studies for an initial indication of the prevention of hospital re-admission following acute decompensated heart failure. » More

Upcoming Events

Presentation of clinical data at the American College of Cardiology (ACC) 61th Scientific Session » More

» Download Poster

August 16, 2012 - Nile Announces Death of Executive Chairman Richard B. Brewer, A Longtime Biotechnology Leader and Innovator » Read

August 14, 2012 - Nile Therapeutics Reports 2012 Second Quarter Financial Results » Read

August 2, 2012 - Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director » Read

Interested investors or potential investors may conveniently receive E-mail alert messages whenever certain new company information is posted to this site. To automatically receive Nile Therapeutics, Inc. e-mail alerts, enter your e-mail address and click on the Subscribe button.